EUVIMEDEUVIMED entdecken
Crossref

Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer

Botai Li, Peng Wei, Bowen Xie, Xuan Zhong, Xiaoshuang Wang, Xinyi Lou, Ting Zhang, Chen Dong

Cancer Letters · 2026-06 · 648 · 218464

DOI: 10.1016/j.canlet.2026.218464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-06. Verfasst von Botai Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China; Westlake Un…. Hauptthemen laut MEDLINE: Cyclin B1, Pancreatic Neoplasms, CDC2 Protein Kinase, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University, China Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapies, especially immune checkpoint blockade, has achieved considerable success in multiple cancers; however, patients with "cold tumors", in particular pancreatic cancer, rarely respond, largely due to insufficient T cell activation and infiltration within the tumor microenvironment (TME). To understand the mechanisms whereby tumor cells regulate T cell activation, we conducted an in vivo CRISPR-Cas9 screen, and identified the CDK1/Cyclin B1 complex as a previously unrecognized tumor-intrinsic driver of immune evasion in pancreatic cancer. Genetic ablation or pharmacological inhibition of the CDK1/Cyclin B1 complex induced a T cell-inflamed TME, which synergized with PD-1 blockade to suppress tumor growth. Mechanistically, loss of Ccnb1 reduced phosphorylation of the retinoblastoma protein (Rb) at S249/T252 residues, and restored NF-κB activity, which elevated the production of granulocyte-macrophage colony-stimulating factor (GM-CSF), and promoted the recruitment and activation of conventional type 1 dendritic cells. Collectively, these findings uncover the CDK1/Cyclin B1 complex involved in tumor immune evasion and provide a compelling rationale for combining CDK1/Cyclin B1 inhibition with PD-1 blockade in the treatment of pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin B1Pancreatic NeoplasmsCDC2 Protein KinaseImmunotherapyAnimalsHumansMiceTumor MicroenvironmentCell Line, TumorTumor EscapeT-Lymphocytes

Substanzen

Cyclin B1CDC2 Protein KinaseCCNB1 protein, humanCDK1 protein, human

Autor:innen und Institutionen

  • Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China; Westlake University School of Medicine and New Cornerstone Science Laboratory, Ha…
  • Institute for Immunology and School of Medicine, Tsinghua University, Beijing, 100084, China.
  • Westlake University School of Medicine and New Cornerstone Science Laboratory, Hangzhou, Zhejiang, 310030, China; Institute for Immunology and School of Medicine, Tsinghua University, Beijing, 100084, China.
  • School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine - Affiliated Renji Hospital, Shanghai, 200127, China. Electronic address: zhangting@shsmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University
  • China Postdoctoral Science Foundation
  • Chinese Academy of Medical Sciences Initiative for Innovative Medicine
  • National Postdoctoral Program for Innovative Talents

Zitieren

APA

Li, B., Wei, P., Xie, B., Zhong, X., Wang, X., Lou, X., Zhang, T., & Dong, C. (2026). Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer. Cancer Letters, 648, 218464. https://doi.org/10.1016/j.canlet.2026.218464

Vancouver

Li B, Wei P, Xie B, Zhong X, Wang X, Lou X, et al. Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer. Cancer Letters. 2026;648:218464. doi:10.1016/j.canlet.2026.218464

BibTeX
@article{Li2026,
  author = {Li, Botai and Wei, Peng and Xie, Bowen and Zhong, Xuan and Wang, Xiaoshuang and Lou, Xinyi and Zhang, Ting and Dong, Chen},
  title = {Targeting tumor-intrinsic CDK1/Cyclin B1 complex improves responses to immunotherapy in pancreatic cancer},
  journal = {Cancer Letters},
  year = {2026},
  volume = {648},
  pages = {218464},
  doi = {10.1016/j.canlet.2026.218464}
}
Kostenlos starten →